Galectin-3 May Be a Biomarker for Cardiovascular Disease in RA
MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA
Rheumatoid Arthritis Risk Lower Among Smokers Who Quit
Upadacitinib at the FDA
The Effects of Early RA Treatment on CVD
B Cell-Directed Therapy May Delay RA Development in High-Risk Patients
RA Effectiveness Differs Among Non-TNF Inhibitors
Reminder: How to Handle Part D Prior Authorization Requests
FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
- 1
- 2
- 3
- …
- 19
- Next Page »